Pepscan Therapeutics establishes a Research Collaboration with Tibotec Pharmaceuticals

15-Sep-2010 - Pepscan Therapeutics announced that it has signed a Research and License Agreement with Tibotec Pharmaceuticals. Under the agreement Pepscan using its CLIPS technology will work with Tibotec to develop novel therapeutic peptides against an undisclosed target. Under the terms of the agreement, ...

Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals

20-Jul-2009 - Gilead Sciences, Inc. announced that it has entered into a license and collaboration agreement with Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose antiretroviral regimen containing Gilead’s Truvada® (emtricitabine and tenofovir disoproxil ...

INTELENCE (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy

02-Sep-2008 - The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCE(TM) (etravirine). INTELENCE is a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) showing efficacy in patients with NNRTI-resistant HIV. Also known as TMC125, ...

Candidate Drug designated within the Medivir Tibotec Collaboration

02-Jan-2006 - The Hepatitis C Virus (HCV) collaboration of Medivir AB with Tibotec Pharmaceuticals Ltd has recently designated a Candidate Drug (CD). The aim of the research collaboration is to identify and develop orally active inhibitors of the HCV protease NS3/4A. The collaboration was initiated in November ...

Tibotec Discontinues Exploratory Trial With TMC125

Phase III Registration Studies Continue

01-Dec-2005 - Tibotec Pharmaceuticals Ltd. announced the discontinuation of a single exploratory open-label phase II study involving TMC125, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Discontinuation of this study has no impact on the phase III registration studies of TMC125, which are currently ...

Crucell Announces PER.C6® Licensing Agreement with Tibotec

25-Nov-2005 - Dutch biotechnology company Crucell N.V. announced that it has signed a PER.C6® license agreement with Ireland-based Tibotec Pharmaceuticals Ltd. The non-exclusive agreement allows Tibotec to use the PER.C6® cell line for research in the field of virology. Under the terms of the agreement, ...

Tibotec Pharmaceuticals Ltd. presented data on investigational HIV Compounds

01-Mar-2005 - Tibotec presented interim Phase IIB results on TMC114, a protease inhibitor (PI) studied in heavily treatment-experienced patients. Tibotec also presented data on a novel class of nucleotide-competitive reverse transcriptase inhibitors (NcRTIs). The company is also developing a compound for ...